
MetLife is an insurance-life business based in the US. MetLife shares (MET) are listed on the NYSE and all prices are listed in US Dollars.
How to buy MetLife stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MET. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
What's in this guide?
- MET shares summary
- Compare share dealing platforms
- Is MET stock a buy or sell?
- Stock performance over time
- Is MET suitable for ethical investing?
- Are MET shares over-valued?
- MetLife's financials
- How volatile are MET shares?
- Does MetLife pay a dividend?
- Have MET shares ever split?
- Other common questions
MetLife stock price (NYSE: MET)
Use our graph to track the performance of MET stocks over time.MetLife shares at a glance
Latest market close | $71.26 |
---|---|
52-week range | $56.17 - $76.81 |
50-day moving average | $72.57 |
200-day moving average | $67.51 |
Wall St. target price | $83.43 |
PE ratio | 24.488 |
Dividend yield | $1.98 (2.85%) |
Earnings per share (TTM) | $2.91 |
Buy MetLife stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy MetLife stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MetLife price performance over time
Historical closes compared with the close of $71.26 from 2023-02-07
1 week (2023-02-02) | 2.22% |
---|---|
1 month (2023-01-05) | N/A |
3 months (2022-11-09) | -2.08% |
6 months (2022-08-05) | N/A |
1 year (2022-02-09) | 1.19% |
---|---|
2 years (2021-02-09) | 32.94% |
3 years (2020-02-07) | 48.25% |
5 years (2018-02-08) | 92.89% |
Is MetLife stock undervalued or overvalued?
Valuing MetLife stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MetLife's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MetLife's P/E ratio
MetLife's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, MetLife shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
MetLife's PEG ratio
MetLife's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.1936. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MetLife's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
MetLife's EBITDA
MetLife's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4 billion.
The EBITDA is a measure of a MetLife's overall financial performance and is widely used to measure a its profitability.
MetLife financials
Revenue TTM | $69.9 billion |
---|---|
Operating margin TTM | 5.61% |
Gross profit TTM | $15.6 billion |
Return on assets TTM | 0.34% |
Return on equity TTM | 5.38% |
Profit margin | 3.63% |
Book value | $34.71 |
Market capitalisation | $55.5 billion |
TTM: trailing 12 months
MetLife share dividends
Dividend payout ratio: 29.24% of net profits
Recently MetLife has paid out, on average, around 29.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.85% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), MetLife shareholders could enjoy a 2.85% return on their shares, in the form of dividend payments. In MetLife's case, that would currently equate to about $1.98 per share.
While MetLife's payout ratio might seem fairly standard, it's worth remembering that MetLife may be investing much of the rest of its net profits in future growth.
MetLife's most recent dividend payout was on 13 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 5 February 2023 (the "ex-dividend date").
Have MetLife's shares ever split?
MetLife's shares were split on a 1122:1000 basis on 6 August 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1122 shares. This wouldn't directly have changed the overall worth of your MetLife shares – just the quantity. However, indirectly, the new 10.9% lower share price could have impacted the market appetite for MetLife shares which in turn could have impacted MetLife's share price.
MetLife share price volatility
Over the last 12 months, MetLife's shares have ranged in value from as little as $56.1669 up to $76.8058. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while MetLife's is 1.0805. This would suggest that MetLife's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
MetLife overview
MetLife, Inc. , a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U. S. ; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives.
MetLife in the news
Prudential Financial (PRU) Q4 Earnings Miss, Decrease Y/Y

Majority of Plan Sponsors Considering Buyouts of Retiree Life, Medical Obligations
Metlife’s Vietnamese Partner Looking to Revive JV Stake Sale
Frequently asked questions
What percentage of MetLife is owned by insiders or institutions?Currently 15.969% of MetLife shares are held by insiders and 75.665% by institutions. When does the fiscal year end for MetLife?
MetLife's fiscal year ends in December. Where is MetLife based?
MetLife's address is: 200 Park Avenue, New York, NY, United States, 10166-0188 What is MetLife's ISIN number?
MetLife's international securities identification number is: US59156R1086 What is MetLife's CUSIP number?
MetLife's Committee on Uniform Securities Identification Procedures number is: 59156R116
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert